Literature DB >> 10994887

Preserving function in Duchenne dystrophy with long-term pulse prednisone therapy.

G T Carter1, C M McDonald.   

Abstract

We report a case of a patient with Duchenne muscular dystrophy who was treated with intermittent pulse prednisone for severe asthma from age 3 to 17 yr and had remarkable preservation of skeletal muscle function. He had a maternal uncle with Duchenne muscular dystrophy who had the identical familial deletion mutation and died at age 19 of respiratory failure. Compared with his untreated uncle, our patient remains partially ambulatory at age 20. This case provides interesting, albeit anecdotal, evidence of considerable clinical benefit from pulse prednisone used on a much longer term basis than has been previously studied and promotes the need for further investigation on this type of therapy in Duchenne muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10994887     DOI: 10.1097/00002060-200009000-00009

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


  9 in total

Review 1.  Exacerbation of pathology by oxidative stress in respiratory and locomotor muscles with Duchenne muscular dystrophy.

Authors:  John M Lawler
Journal:  J Physiol       Date:  2011-03-08       Impact factor: 5.182

2.  Classification of the gait patterns of boys with Duchenne muscular dystrophy and their relationship to function.

Authors:  Susan Sienko Thomas; Cathleen E Buckon; Alina Nicorici; Anita Bagley; Craig M McDonald; Michael D Sussman
Journal:  J Child Neurol       Date:  2010-06-29       Impact factor: 1.987

Review 3.  Cardiopulmonary support in duchenne muscular dystrophy.

Authors:  Josef Finsterer
Journal:  Lung       Date:  2006 Jul-Aug       Impact factor: 2.584

4.  Developing standardized corticosteroid treatment for Duchenne muscular dystrophy.

Authors:  Michela Guglieri; Kate Bushby; Michael P McDermott; Kimberly A Hart; Rabi Tawil; William B Martens; Barbara E Herr; Elaine McColl; Jennifer Wilkinson; Janbernd Kirschner; Wendy M King; Michele Eagle; Mary W Brown; Tracey Willis; Deborah Hirtz; Perry B Shieh; Volker Straub; Anne-Marie Childs; Emma Ciafaloni; Russell J Butterfield; Iain Horrocks; Stefan Spinty; Kevin M Flanigan; Nancy L Kuntz; Giovanni Baranello; Helen Roper; Leslie Morrison; Jean K Mah; Adnan Y Manzur; Craig M McDonald; Ulrike Schara; Maja von der Hagen; Richard J Barohn; Craig Campbell; Basil T Darras; Richard S Finkel; Giuseppe Vita; Imelda Hughes; Tiziana Mongini; Elena Pegoraro; Matthew Wicklund; Ekkehard Wilichowski; W Bryan Burnette; James F Howard; Hugh J McMillan; Mathula Thangarajh; Robert C Griggs
Journal:  Contemp Clin Trials       Date:  2017-04-24       Impact factor: 2.226

5.  Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy.

Authors:  Sunkyung Kim; Yong Zhu; Paul A Romitti; Deborah J Fox; Daniel W Sheehan; Rodolfo Valdez; Dennis Matthews; Brent J Barber
Journal:  Neuromuscul Disord       Date:  2017-06-05       Impact factor: 4.296

6.  Cytoplasmic gamma-actin expression in diverse animal models of muscular dystrophy.

Authors:  Laurin M Hanft; Daniel J Bogan; Ulrike Mayer; Stephen J Kaufman; Joe N Kornegay; James M Ervasti
Journal:  Neuromuscul Disord       Date:  2007-05-01       Impact factor: 4.296

Review 7.  Contribution of oxidative stress to pathology in diaphragm and limb muscles with Duchenne muscular dystrophy.

Authors:  Jong-Hee Kim; Hyo-Bum Kwak; LaDora V Thompson; John M Lawler
Journal:  J Muscle Res Cell Motil       Date:  2012-10-28       Impact factor: 2.698

8.  Improving clinical trial design for Duchenne muscular dystrophy.

Authors:  Luciano Merlini; Patrizia Sabatelli
Journal:  BMC Neurol       Date:  2015-08-26       Impact factor: 2.474

Review 9.  Corticosteroid Treatment Impact on Spinal Deformity in Duchenne Muscular Dystrophy.

Authors:  Ilaria Sanzarello; Luciano Merlini; Francesco Traina; Michele Attilio Rosa; Cesare Faldini
Journal:  Int Sch Res Notices       Date:  2014-10-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.